List of Trokendi Xr drug patents
Trokendi Xr is owned by Supernus Pharms.
Trokendi Xr contains Topiramate.
Trokendi Xr has a total of 10 drug patents out of which 0 drug patents have expired.
Trokendi Xr was authorised for market use on 16 August, 2013.
Trokendi Xr is available in capsule, extended release;oral dosage forms.
Trokendi Xr can be used as use of trokendi xr for the treatment of epilepsy; use of trokendi xr for prophylactic treatment of migraine, use of trokendi xr for prophylactic treatment of migraine; use of trokendi xr for the treatment of epilepsy, use of trokendi xr for prophylactic treatment of migraine; treatment of epilepsy, treatment of epilepsy; use of trokendi xr for prophylactic treatment of migraine.
The generics of Trokendi Xr are possible to be released after 04 April, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10314790 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US9622983 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8663683 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8992989 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8889191 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US9549940 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8298580 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8877248 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US9555004 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8298576 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Apr, 2028
(5 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 16 August, 2013
Treatment: Use of trokendi xr for the treatment of epilepsy; Use of trokendi xr for prophylactic treatment of migraine; Treatment of epilepsy
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic